Cargando…
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly emerging a promising new treatment for haematological and non-haematological malignancies. CAR-T therapy can induce rapid and durable clinical responses but is associated with unique acute toxicities. Moreover, C...
Autores principales: | Fu, Wenyan, Lei, Changhai, Liu, Shuowu, Cui, Yingshu, Wang, Chuqi, Qian, Kewen, Li, Tian, Shen, Yafeng, Fan, Xiaoyan, Lin, Fangxing, Ding, Min, Pan, Mingzhu, Ye, Xuting, Yang, Yongji, Hu, Shi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761190/ https://www.ncbi.nlm.nih.gov/pubmed/31554797 http://dx.doi.org/10.1038/s41467-019-12321-3 |
Ejemplares similares
-
CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021) -
CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
por: Jin, Chuan, et al.
Publicado: (2022) -
Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
por: Sajman, Julia, et al.
Publicado: (2023) -
Rapid manufacturing of non-activated potent CAR T cells
por: Ghassemi, Saba, et al.
Publicado: (2022) -
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)